Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noah Rodriguez

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Gynecologic Oncology|March 23, 2011
Carcinosarcoma of the ovary: a case-control studyJ Alejandro Rauh-Hain, Whitfield B Growdon, Noah Rodriguez, et al.
American Journal of Public Health|June 28, 2022
Intersectional Stigma and Prevention Among Gay, Bisexual, and Same Gender-Loving Men in New York City, 2020: System Dynamics ModelsPriscila Lutete, David W Matthews, Nasim S Sabounchi, et al.
Gynecologic Oncology|February 16, 2012
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapyNoah Rodriguez, J Alejandro Rauh-Hain, Melina Shoni, et al.
EMBO Molecular Medicine|June 19, 2012
Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cellsNoah Rodriguez, Junzheng Yang, Kathleen Hasselblatt, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2009
Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancerLiangdan Tang, Junzheng Yang, Shu-Kay Ng, et al.
Cancer|November 20, 2016
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data studyBunja J Rungruang, Austin Miller, Thomas C Krivak, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Gynecologic Oncology|March 23, 2011
Carcinosarcoma of the ovary: a case-control studyJ Alejandro Rauh-Hain, Whitfield B Growdon, Noah Rodriguez, et al.
American Journal of Public Health|June 28, 2022
Intersectional Stigma and Prevention Among Gay, Bisexual, and Same Gender-Loving Men in New York City, 2020: System Dynamics ModelsPriscila Lutete, David W Matthews, Nasim S Sabounchi, et al.
Gynecologic Oncology|February 16, 2012
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapyNoah Rodriguez, J Alejandro Rauh-Hain, Melina Shoni, et al.
EMBO Molecular Medicine|June 19, 2012
Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cellsNoah Rodriguez, Junzheng Yang, Kathleen Hasselblatt, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2009
Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancerLiangdan Tang, Junzheng Yang, Shu-Kay Ng, et al.
Cancer|November 20, 2016
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data studyBunja J Rungruang, Austin Miller, Thomas C Krivak, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Pageof 2